TD Asset Management Inc Sells 49,200 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Key Points

• TD Asset Management Inc significantly reduced its stake in Oruka Therapeutics by 51.7%, now holding 45,876 shares valued at approximately $471,000.
• Despite the decrease by TD Asset Management, several other institutions such as FMR LLC and Vanguard Group Inc. increased their holdings in Oruka Therapeutics, with Vanguard raising its stake by over 4,161%.
• Analysts have a generally positive outlook on Oruka Therapeutics, with a consensus rating of "Buy" and a target price of $40.38, influenced by multiple buy ratings from research firms.

TD Asset Management Inc trimmed its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 51.7% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 45,876 shares of the company's stock after selling 49,200 shares during the period. TD Asset Management Inc owned about 0.12% of Oruka Therapeutics worth $471,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth approximately $54,000. Squarepoint Ops LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $236,000. Jane Street Group LLC bought a new stake in Oruka Therapeutics during the fourth quarter worth $343,000. Cannon Global Investment Management LLC purchased a new position in Oruka Therapeutics in the first quarter worth $195,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Oruka Therapeutics in the fourth quarter worth $384,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Monday, July 21st. BTIG Research began coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They set a "buy" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Stock Down 3.7%

Oruka Therapeutics stock traded down $0.51 during midday trading on Friday, reaching $13.16. The stock had a trading volume of 21,268 shares, compared to its average volume of 252,611. The firm has a market capitalization of $492.71 million, a PE ratio of -2.92 and a beta of -0.35. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $52.32. The firm's 50-day moving average price is $13.06 and its 200 day moving average price is $11.45.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.